BG
DRNA

BlackRock Group’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

BlackRock Group’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-3,277
Closed -$54K – 2902
2014
Q4 		$54K Buy
+3,277
New +$37.8K ﹤0.01% 2771
2014
Q2 		– Sell
-20,500
Closed -$579K – 2886
2014
Q1 		$579K Buy
+20,500
New +$762K ﹤0.01% 2196

Other funds holding DRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock Group's DRNA Position: Q1 2015 in Review

BlackRock Group sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q1 2015, closing a stake of 3,277 shares — an estimated $54K sold.

BlackRock Group first reported a position in DRNA in Q1 2014 and held it in 2 quarters. The position peaked at $579K in Q1 2014. 54 funds tracked by Wall St. Rank hold DRNA as of Q1 2015.

  • BlackRock Group reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q1 2015 after selling out during the quarter.
  • BlackRock Group sold 3,277 Dicerna Pharmaceuticals, Inc. shares in Q1 2015, an estimated $54K.
  • BlackRock Group first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2014 and held it in 2 quarters.
  • BlackRock Group's Dicerna Pharmaceuticals, Inc. position peaked at $579K in Q1 2014.
  • 54 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q1 2015.

Based on BlackRock Group's 13F filing for Q1 2015, filed 13 May 2015.